Latest & greatest articles for copd

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on copd or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on copd and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for copd

321. Effects of smoking and solid-fuel use on COPD, lung cancer, and tuberculosis in China: a time-based, multiple risk factor, modelling study.

Effects of smoking and solid-fuel use on COPD, lung cancer, and tuberculosis in China: a time-based, multiple risk factor, modelling study. BACKGROUND: Chronic obstructive pulmonary disease (COPD), lung cancer, and tuberculosis are three leading causes of death in China, where prevalences of smoking and solid-fuel use are also high. We aimed to predict the effects of risk-factor trends on COPD, lung cancer, and tuberculosis. METHODS: We used representative data sources to estimate past trends (...) in smoking and household solid-fuel use and to construct a range of future scenarios. We obtained the aetiological effects of risk factors on diseases from meta-analyses of epidemiological studies and from large studies in China. We modelled future COPD and lung cancer mortality and tuberculosis incidence, taking into account the accumulation of hazardous effects of risk factors on COPD and lung cancer over time, and dependency of the risk of tuberculosis infection on the prevalence of disease. We

Lancet2008 Full Text: Link to full Text with Trip Pro

322. Nursing care in the chronic phase of COPD: a call for innovative disciplinary research

Nursing care in the chronic phase of COPD: a call for innovative disciplinary research 18578803 2008 06 26 2008 08 21 2008 06 26 1365-2702 17 7B 2008 Apr Journal of clinical nursing J Clin Nurs Nursing care in the chronic phase of COPD: a call for innovative disciplinary research. 272-90 10.1111/j.1365-2702.2007.02271.x The literature on nursing care in nurse clinics that focus on chronic management of chronic obstructive pulmonary disease (COPD) is analysed and synthesised with the purpose (...) of advancing research of practice in nurse clinics. Along with the rising prevalence of COPD and a growing recognition of long-lasting, comprehensive and complex healthcare needs of people with COPD and their families, nurses are challenged to restructure their practice. An integrated review was conducted. The databases searched were NCBI's PubMed database, Scopus, CINAHL and Web of Science from 1996 to 2006. Terms searched were 'COPD' and 'nurse managed clinic' with all subheadings. A nurse had

EvidenceUpdates2008

323. Impact of COPD on outcome among patients with complicated peptic ulcer

Impact of COPD on outcome among patients with complicated peptic ulcer 18339786 2008 06 24 2008 07 31 2008 06 24 0012-3692 133 6 2008 Jun Chest Chest Impact of COPD on outcome among patients with complicated peptic ulcer. 1360-6 10.1378/chest.07-2543 COPD is associated with an increased risk of peptic ulcer disease, but limited data exist on whether COPD influences short-term mortality among patients with bleeding and a perforated peptic ulcer. We examined the association between COPD and 30 (...) -day mortality following bleeding and perforation of a peptic ulcer. We identified all patients who had been hospitalized with a first-time diagnosis of peptic ulcer perforation (n = 2,033) or bleeding (n = 7,486) in northern Denmark between 1991 and 2004. Information on COPD, comorbidities, and filled prescriptions was obtained from medical databases. Mortality was ascertained using the Danish Civil Registration System. We computed the cumulative 30-day mortality rates for ulcer patients with COPD

EvidenceUpdates2008

324. Contemporary Management of Acute Exacerbations of COPD: A Systematic Review and Metaanalysis

Contemporary Management of Acute Exacerbations of COPD: A Systematic Review and Metaanalysis 18321904 2008 03 06 2008 04 22 2008 09 03 0012-3692 133 3 2008 Mar Chest Chest Contemporary management of acute exacerbations of COPD: a systematic review and metaanalysis. 756-66 10.1378/chest.07-1207 Systemic corticosteroids, antibiotics, and noninvasive positive pressure ventilation (NPPV) are recommended for patients with acute exacerbation of COPD. However, their clinical benefits in various (...) % CI, 0.30 to 0.66), and the length of hospitalization by 1.9 days (95% CI, 0.0 to 3.9). For acute COPD exacerbations, systemic corticosteroids are effective in reducing treatment failures, while antibiotics reduce mortality and treatment failures in those requiring hospitalization and NPPV reduces the risk of intubation and in-hospital mortality, especially in those who demonstrate respiratory acidosis. Quon Bradley S BS Department of Medicine, Respiratory Division, University of British Columbia

EvidenceUpdates2008

326. Review: anticholinergics but not B2 agonists reduce exacerbations requiring hospital admission and respiratory deaths in COPD

Review: anticholinergics but not B2 agonists reduce exacerbations requiring hospital admission and respiratory deaths in COPD Review: anticholinergics but not β2 agonists reduce exacerbations requiring hospital admission and respiratory deaths in COPD | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password (...) * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: anticholinergics but not β2 agonists reduce exacerbations requiring hospital admission and respiratory deaths in COPD Article Text Therapeutics Review: anticholinergics but not β 2 agonists reduce exacerbations requiring hospital admission

Evidence-Based Medicine (Requires free registration)2008

327. [Appropriateness use standards for health technologies. Development of explicit criteria for indication of admission in COPD exacerbation]

[Appropriateness use standards for health technologies. Development of explicit criteria for indication of admission in COPD exacerbation] Estandares de uso adecuado de tecnologias sanitarias. Creacion de criterios explicitos de indicacion de ingreso hospitalario en la exacerbacion de EPOC [Appropriateness use standards for health technologies. Development of explicit criteria for indication of admission in COPD exacerbation] Estandares de uso adecuado de tecnologias sanitarias. Creacion de (...) criterios explicitos de indicacion de ingreso hospitalario en la exacerbacion de EPOC [Appropriateness use standards for health technologies. Development of explicit criteria for indication of admission in COPD exacerbation] Quintana JM, Garcia Gutierrez, Aguirre U, Gonzalez Hernandez N, Grupo adecuacion-EPOC, Unidad de investigacion-CIBER Epidemiologia y Salud Publica (CIBERESP), Hospital Galdakao-Usansolo, Bizkaia Citation Quintana JM, Garcia Gutierrez, Aguirre U, Gonzalez Hernandez N, Grupo

Health Technology Assessment (HTA) Database.2008

330. Improving outcomes for COPD patients with mild-to-moderate anxiety and depression: a systematic review of cognitive behavioural therapy

Improving outcomes for COPD patients with mild-to-moderate anxiety and depression: a systematic review of cognitive behavioural therapy Improving outcomes for COPD patients with mild-to-moderate anxiety and depression: a systematic review of cognitive behavioural therapy Improving outcomes for COPD patients with mild-to-moderate anxiety and depression: a systematic review of cognitive behavioural therapy Coventry PA, Gellatly JL CRD summary This review concluded that there was limited evidence (...) that cognitive behavioural therapy, when used with exercise and education, could contribute to significant reductions in anxiety and depression in patients with clinically stable and severe chronic obstructive pulmonary disease. These conclusions are likely to be reliable although, as the authors stated, an adequately powered RCT is required to confirm these findings. Authors' objectives To evaluate the effectiveness of cognitive behavioural therapy in reducing mild-to-moderate anxiety and depression

DARE.2008

331. Short-course antibiotic treatment in acute exacerbations of chronic bronchitis and COPD: a meta-analysis of double-blind studies

Short-course antibiotic treatment in acute exacerbations of chronic bronchitis and COPD: a meta-analysis of double-blind studies Short-course antibiotic treatment in acute exacerbations of chronic bronchitis and COPD: a meta-analysis of double-blind studies Short-course antibiotic treatment in acute exacerbations of chronic bronchitis and COPD: a meta-analysis of double-blind studies El Moussaoui R, Roede B M, Speelman P, Bresser P, Prins J M, Bossuyt P M CRD summary The authors concluded (...) that short courses of antibiotic therapy (five days or less) are as effective as conventional courses in the treatment of mild to moderate acute exacerbations of chronic obstructive pulmonary disease and chronic bronchitis. The review was well conducted and these conclusions appear reliable. Authors' objectives To determine whether a short course of antibiotics (five days or less) is as effective as a conventional longer course in patients with acute exacerbation of chronic obstructive pulmonary disease

DARE.2008

332. Safety of long-acting beta-agonists in stable COPD: a systematic review

Safety of long-acting beta-agonists in stable COPD: a systematic review Safety of long-acting beta-agonists in stable COPD: a systematic review Safety of long-acting beta-agonists in stable COPD: a systematic review Rodrigo G J, Nannini L J, Rodriguez-Roisin R CRD summary The authors concluded that long-acting bronchodilators were beneficial in patients with stable moderate to severe COPD and did not increase the risk of respiratory death. The evidence also indicated that tiotropium (...) was superior to LABAs. This was a generally well-conducted review. The authors' conclusions appeared to reflect the evidence and was likely to be reliable. Authors' objectives To assess the safety and efficacy of long-acting bronchodilators – long-acting Beta 2-agonists (LABAs) – compared to placebo and anticholinergics in patients with chronic obstructive pulmonary disease (COPD). Searching MEDLINE, EMBASE, CINAHL and the Cochrane Controlled Trials Register were searched for articles through to 2007

DARE.2008

333. Contemporary management of acute exacerbations of COPD: a systematic review and metaanalysis

Contemporary management of acute exacerbations of COPD: a systematic review and metaanalysis Contemporary management of acute exacerbations of COPD: a systematic review and metaanalysis Contemporary management of acute exacerbations of COPD: a systematic review and metaanalysis Quon B S, Gan W Q, Sin D D CRD summary This review, which assessed the effectiveness of using systemic corticosteroids, antibiotics, and noninvasive positive pressure ventilation (NPPV) for patients with acute (...) exacerbation of chronic obstructive pulmonary disease (COPD), concluded that all three types of treatment can be effective. The authors' conclusions should be interpreted with some caution in light of language and publication bias issues. Authors' objectives To evaluate the effectiveness of systemic corticosteroids, antibiotics and noninvasive positive pressure ventilation (NPPV) for patients with acute exacerbation of chronic obstructive pulmonary disease (COPD). Searching The MEDLINE and EMBASE databases

DARE.2008

334. Review: corticosteroids plus LABAs reduce exacerbations and mortality more than steroids alone in COPD

Review: corticosteroids plus LABAs reduce exacerbations and mortality more than steroids alone in COPD Review: corticosteroids plus LABAs reduce exacerbations and mortality more than steroids alone in COPD | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search (...) for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: corticosteroids plus LABAs reduce exacerbations and mortality more than steroids alone in COPD Article Text Therapeutics Review: corticosteroids plus LABAs reduce exacerbations and mortality more than steroids alone in COPD Statistics from Altmetric.com No Altmetric data available

Evidence-Based Medicine (Requires free registration)2008

335. Outcomes for COPD pharmacological trials: from lung function to Biomarkers

Outcomes for COPD pharmacological trials: from lung function to Biomarkers Options

European Respiratory Society2008

336. Review: walking aids, chest-wall vibration, and neuroelectrical muscle stimulation relieve breathlessness in COPD

Review: walking aids, chest-wall vibration, and neuroelectrical muscle stimulation relieve breathlessness in COPD Review: walking aids, chest-wall vibration, and neuroelectrical muscle stimulation relieve breathlessness in COPD | Evidence-Based Nursing This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password (...) * your user name or password? Search for this keyword Search for this keyword Main menu Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: walking aids, chest-wall vibration, and neuroelectrical muscle stimulation relieve breathlessness in COPD Article Text Treatment Review: walking aids, chest-wall vibration, and neuroelectrical muscle stimulation relieve

Evidence-Based Nursing (Requires free registration)2008

337. Review: corticosteroids plus long-acting Beta-agonists reduce exacerbations more than long-acting Beta-agonists alone in COPD

Review: corticosteroids plus long-acting Beta-agonists reduce exacerbations more than long-acting Beta-agonists alone in COPD Review: corticosteroids plus long-acting β-agonists reduce exacerbations more than long-acting β-agonists alone in COPD | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your (...) user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: corticosteroids plus long-acting β-agonists reduce exacerbations more than long-acting β-agonists alone in COPD Article Text Therapeutics Review: corticosteroids plus long-acting β-agonists reduce exacerbations more than long-acting β-agonists alone

Evidence-Based Medicine (Requires free registration)2008

338. Review: long-acting inhaled therapies and pulmonary rehabilitation are effective in stable COPD

Review: long-acting inhaled therapies and pulmonary rehabilitation are effective in stable COPD Review: long-acting inhaled therapies and pulmonary rehabilitation are effective in stable COPD | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search (...) for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: long-acting inhaled therapies and pulmonary rehabilitation are effective in stable COPD Article Text Therapeutics Review: long-acting inhaled therapies and pulmonary rehabilitation are effective in stable COPD Statistics from Altmetric.com No Altmetric data available for this article. Request permissions If you wish

Evidence-Based Medicine (Requires free registration)2008

339. Implications of prognostic pessimism in patients with chronic obstructive pulmonary disease (COPD) or asthma admitted to intensive care in the UK within the COPD and asthma outcome study (CAOS): multicentre observational cohort study.

Implications of prognostic pessimism in patients with chronic obstructive pulmonary disease (COPD) or asthma admitted to intensive care in the UK within the COPD and asthma outcome study (CAOS): multicentre observational cohort study. OBJECTIVE: To determine whether clinicians' prognoses in patients with severe acute exacerbations of obstructive lung disease admitted to intensive care match observed outcomes in terms of survival. DESIGN: Prospective cohort study. SETTING: 92 intensive (...) care units and three respiratory high dependency units in the United Kingdom. PARTICIPANTS: 832 patients aged 45 years and older with breathlessness, respiratory failure, or change in mental status because of an exacerbation of COPD, asthma, or a combination of the two. MAIN OUTCOME MEASURES: Outcome predicted by clinicians. Observed survival at 180 days. RESULTS: 517 patients (62%) survived to 180 days. Clinicians' prognoses were pessimistic, with a mean predicted survival of 49% at 180 days

BMJ2007 Full Text: Link to full Text with Trip Pro

340. Formoterol (Easyhaler) - relief of broncho-obstructive symptoms in patients with chronic obstructive pulmonary diesease (COPD)

Formoterol (Easyhaler) - relief of broncho-obstructive symptoms in patients with chronic obstructive pulmonary diesease (COPD) Scottish Medicines Consortium formoterol 12 micrograms metered dose inhaler (Atimos® Modulite ® ) No. (349/07) Trinity-Chiesi Ltd Product Update 9 February 2007 (Issued October 2007) The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees on its use in NHS Scotland (...) . The advice is summarised as follows: ADVICE: following an abbreviated submission formoterol 12 micrograms metered dose inhaler (Atimos® Modulite ® ) is accepted for use in NHS Scotland for the relief of broncho-obstructive symptoms in patients with chronic obstructive pulmonary disease (COPD). It should be used in patients for whom formoterol is an appropriate choice of long-acting beta-agonist and for whom a metered dose inhaler is an appropriate delivery device. Advice context: No part of this advice

Scottish Medicines Consortium2007